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Objectives: The human genome encodes many long intergenic noncoding RNAs (lincRNAs). However, their bi-
ological functions, molecular mechanisms and prognostic values associated with bladder cancer remain to be
elucidated. Here we investigated a lincRNA termed linc-UBC1 (Up-regulated in bladder cancer 1) and evalu-
ated its prognostic value in bladder cancer patients.
Materials and methods: Expression of linc-UBC1 was evaluated by quantitative reverse transcription PCR
(qRT-PCR) in 102 bladder cancer tissue samples and normal adjacent tissues. The functions of linc-UBC1 on
cell proliferation, migration, invasion, colony formation, tumorigenicity andmetastatic potential were evaluated
by knockdown strategy in vitro and in vivo. RNA immunoprecipitation (RIP) was performed to conﬁrm that
linc-UBC1 physically associates with EZH2 and SUZ12, core components of polycomb repressive complex 2
(PRC2). Chromatin immunoprecipitation (ChIP) was conducted to examine histone modiﬁcation status.
Results: qRT-PCR conﬁrmed that linc-UBC1 expression is up-regulated in 60 cases (58.8%) in bladder cancer tis-
sues compared with normal adjacent tissues, and its overexpression correlates with lymph node metastasis and
poor survival. Further functional analysis demonstrated that knockdown of linc-UBC1 attenuates bladder cancer
cell proliferation, motility, invasion, colony formation ability, tumorigenicity and metastatic potential. Impor-
tantly, the inhibitory effect of linc-UBC1 on cell proliferation was also observed in primary bladder cancer
cells obtained from patients. RIP and ChIP assay conﬁrmed that linc-UBC1 physically associates with PRC2 com-
plex and regulates histone modiﬁcation status of target genes.A; linc-UBC1, long intergenic noncoding RNA up-regulated in bladder cancer; PRC2, polycomb repressive complex 2; qRT-PCR,
cer; NAT, normal adjacent tissue; NC, negative control; EdU, ethynyl deoxyuridine; RIP, RNA immunoprecipitation; ChIP,
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Bladder cancer is one of the most common malignancies and it is
estimated that there are 386,000 new cases and causes about
150,000 deaths worldwide annually [1]. Most bladder cancers are of
urothelial transitional cell origin. Bladder cancer is a heterogeneous
disease which can be categorized into the low-grade papillary tumors
and the high-grade invasive tumors [2]. Lymph node metastasis in-
creases the risk of disease speciﬁc mortality, and once distant metas-
tases occur, the patients' ﬁve-year survival rate will decrease
dramatically to less than 10% [3]. Identiﬁcation of novel molecular
prognostic factors that can predict bladder cancer progression and
metastasis is of great importance in clinical practice.
Long noncoding RNAs (lncRNAs) are deﬁned as those longer than
~200 nucleotides but lack of protein coding capacity. Long intergenic
noncoding RNAs (lincRNAs) are those whose transcription loci are
within genomic interval between two protein coding genes [4]. To
date, thousands of lincRNAs are discovered through chromatin signa-
ture analysis and large scale sequencing [5,6]. Functional studies have
shown that many lincRNAs exhibit diverse biological functions and
show clinical signiﬁcance [7]. Many lincRNAs may play important
roles in cell cycle regulation, cell proliferation, immune response
and embryonic stem cell pluripotency [7]. However, the biological
functions and prognostic values of lincRNAs in bladder cancer are
still largely unexplored.
Chromatin modifying complexes play important roles in epigenetic
regulation of gene expression. Accumulating evidence shows that
many lincRNAs associate with chromatin modifying complexes such
as polycomb repressive complex 1 (PRC1) and PRC2 [8,9], serving as
molecular scalffolds of histone modiﬁcation complexes [10]. Another
study showed that high grade bladder cancer shows an embryonic
stem cell like gene expression signature and PRC2 targets are repressed
frequently, indicating that PRC2 complex is functioning actively in ag-
gressive bladder cancer [11]. Inspired by this, we proposed that
lincRNAs associated with PRC2 complexmay be overexpressed in blad-
der cancer.
In this report, we found that a lincRNA, here we termed linc-UBC1
(Up-regulated in bladder cancer 1), physically associates with PRC2
complex and is frequently overexpressed in bladder cancer tissues.
Moreover, linc-UBC1 expression correlates with lymph node metasta-
sis and poor survival in bladder cancer patients and play important
roles in bladder cancer cell proliferation, migration, invasion, colony
formation, tumorigenicity and metastatic potential.
2. Materials and methods
2.1. Tissue samples
Samples of fresh frozen cancer tissues, together with normal adja-
cent tissues (3 cm away from the tumor), were obtained during surgi-
cal resection from Sun Yat-sen Memorial Hospital of Sun Yat-sen
University. All samples were snap-frozen with liquid nitrogen and
stored at −80 °C until processed. Tissue samples were collected
with written consent from patients, and approved by the Hospital
Ethic Review Committees. All samples were conﬁrmed pathologically.
2.2. Cell culture and transfection
Human bladder cancer cell lines (J82, UMUC-3, HT-1376, T24, 5637,
TCCSUP) used in the study were obtained from American Type CultureCollection (ATCC, Manassas, VA). T24 cell line was cultured in McCoy's
5a Medium Modiﬁed. 5637 were cultured in RPMI 1640. J82, UMUC-3,
TCCSUP and HT-1376were cultured in Dulbecco's modiﬁed eagle's me-
dium (DMEM) (Hyclone). All media were supplemented with 10% fetal
bovine serum (Hyclone) and 1% penicillin/streptomycin(Gibco). Cells
were cultured in a humidiﬁed air atmosphere of 5% CO2 at 37 °C.
Routine tests for mycoplasm infection were negative. Cell transfection
was conducted using lipofectamine 2000 (Life technologies) following
manufacturer's instructions.2.3. Primary culture of bladder cancer cells
Bladder cancer tissues were removed by surgical resection at the
Department of Urology, Sun Yat-sen Memorial Hospital. Tissues
were incubated with DMEM medium (High glucose, Hyclone)
containing 5% FBS and 0.1% collagenase at 37 °C for 4 h to prepare
single cell suspensions. Cells were cultured in a humidiﬁed air atmo-
sphere of 5% CO2 at 37 °C. Tissue samples were collected with written
consent from patients, and approved by the Hospital Ethic Review
Committees.2.4. RNA isolation
Total RNA from cells was isolated using Trizol reagent (Life tech-
nologies) and puriﬁed with GeneJET RNA puriﬁcation kit (Fermentas)
and treated with RNase-free DNase set (QIAGEN) following manufac-
turer's instructions. RNA electrophoresis was conducted to inspect
RNA integrity.2.5. Microarray analysis
For microarray analysis, RNA purity and integrity was analyzed by
Agilent Bioanalyzer 2100 (Agilent). Qualiﬁed total RNA was further
puriﬁed by RNeasy mini kit (QIAGEN) and RNase-free DNase set
(QIAGEN). Total RNA was then ampliﬁed and labeled by Low Input
Quick Amp Labeling Kit, One-Color (Agilent), following the manufac-
turer's instructions. Labeled cRNA were puriﬁed by RNeasy mini kit
(QIAGEN). Each Slide was hybridized with 600 ng Cy3-labeled cRNA
using Gene Expression Hybridization Kit (Agilent) in Hybridization
Oven (Agilent), according to the manufacturer's instructions. After
17 h hybridization, slides were washed in staining dishes (Thermo
Shandon) with Gene Expression Wash Buffer Kit (Agilent), following
the manufacturer's instructions. Slides were scanned by Agilent
Microarray Scanner (Agilent) with default settings, Dye channel:
Green, Scan resolution = 3 μm, 20 bit. Data were extracted with
Feature Extraction software 10.7 (Agilent). Raw data were normal-
ized by Quantile algorithm, Gene Spring Software 11.0 (Agilent).2.6. Quantitative reverse transcription PCR analysis
Reverse transcription was performed using M-MLV reverse tran-
scriptase (Life technologies) and quantitative PCR was performed
with SYBR green master mix (Roche). Relative expression values
were calculated (ΔΔCT method) using GAPDH as a normalizer. The
primer sequences used in the study were listed in Supplementary
Table 1.
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Cells were lysed using RIPA buffer (Pierce) containing protease in-
hibitors cocktail (Roche) and proteins were extracted according to the
manufacturer's instruction. Proteins were separated by electrophoresis
in 10% SDS polyacrylamide gels and transferred to polyvinylidene
ﬂuoride membranes (Millipore). Primary antibodies speciﬁc to EZH2
(1:1000, Abcam), SUZ12 (1:1000, Abcam) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (1:1000, Cell signaling technology)
were used. Horseradish peroxidase-conjugated secondary antibodies
(Cell signaling technology) and an ECL chemiluminescence kit (Pierce)
were used to detect bound antibody.
2.8. Bioinformatic analysis
Coding capacity of linc-UBC1 was analyzed with TESTCODE
(http://www.genomicsplace.com/testcode.html) and 0.74 was used
as a cut-off value. RNA–protein interaction prediction was performed
with RPISeq (http://pridb.gdcb.iastate.edu/RPISeq/) and a score of
over 0.5 was considered positive.
2.9. Nuclear fractionation
For nuclear fractionation, 107 cells were harvested, washed with ice
cold PBS twice and resuspended in 1 ml of ice cold RNase-free PBS, 1 ml
of buffer C1 (1.28 M Sucrose, 40 mMTris, pH 7.5, 20 mMMgCl2, 4% Tri-
ton X-100) and 3 ml of RNase-free water, and incubated for 15 min on
ice. Then cells were centrifuged for 15 min at 2500 rpm, the superna-
tant was discarded and the nuclear pellet was kept for RNA extraction.
2.10. RNA interference
siRNA oligos targeting linc-UBC1 (#1 CCUGUCUACAGACUGAAU
ATT, #2 CCGGAACAAAUGGCUUCAUTT), EZH2 (#1 GCAAAUUCUCG
GUGUCAAATT, #2 GCUGAAGCCUCAAUGUUUATT), SUZ12 (#1 CAUC
GAAACUCCAGAACAATT, #2 GGAUGUAAGUUGUCCAAUATT), and non-
targeting siRNAs (UUCUCCGAACGUGUCACGUTT) were purchased
from GenePharma (Shanghai). siRNA transfections were done with
75 nM siRNA and Lipofectamine 2000 (Life technologies) following
manufacturer's instructions.
2.11. Cell proliferation, cell motility, invasion and colony formation assay
For cell proliferation assay, 2 × 103 cells were plated in quadrupli-
cates in 96-well plates and cell number was calculated using the
MTT assay (Roche). Cell motility assay was performed using the
BD Transwell chambers. For colony formation assay, transfected cells
were placed in a fresh six-well plate andmaintained in DMEMmedium
containing 10% FBS for two weeks and colonies were ﬁxed with metha-
nol and stained with 0.1% crystal violet and counted. In vitro cell inva-
sion assay was performed using the BD BioCoat™ BD Matrigel™
Invasion Chamber (Becton Dickson) according to manufacturer's in-
structions. At least three biological replicates of the experiments were
performed. After that, crystal violet on the transwell membrane was
dissolved in 33% acetic acid solution and measured the absorbance of
crystal violet (OD570 nm).
2.12. Ethynyl deoxyuridine (EdU) incorporation analysis of S-phase cells
S-phase cells' proportion was analyzed using EdU assay kit
(Ribobio), according to the manufacturer's instructions. Brieﬂy, cells
were incubated with 5 μM EdU in DMEM (Hyclone) media
supplementedwith 10% FBS (Hyclone) and 1% penicillin/streptomycin
(Gibco) for 2 h at 37 °C. Then cells were ﬁxed with 4% formaldehyde
for 30 min at room temperature and treated with 0.5% Triton X-100
for 20 min for permeabilization. After washing with PBS for threetimes, the cells were reacted with 1× Apollo® reaction cocktail
(Ribobio) for 30 min. Subsequently, the DNA contents were stained
with Hoechst 33342 (5 μg/ml) for 30 min and visualized under a ﬂuo-
rescent microscope.2.13. Tumorigenicity and tail vein assays in NOD/SCID mice
All experimental procedures involving animals were in accordance
with the Guide for the Care and Use of Laboratory Animals (NIH publi-
cation No. 80-23, revised 1996) and were performed according to the
institutional ethical guidelines for animal experiment. linc-UBC1 knock-
down or NC-transfected UMUC-3 cells (5 × 106) were suspended in
200 μl PBS and then injected subcutaneously into the anterior ﬂank of
the NOD/SCID mice at 5 weeks of age. Four mice were used in each
group. Tumor growth was examined every third day for 3 weeks.
Animals were sacriﬁced and tumor weight was measured. For tail vein
assays, the same amount of transfected cells were injected into the tail
vein of NOD/SCID mice which were sacriﬁced at 3 weeks. Tumor
burden was examined with a microscope and measured by lung wet
weights.2.14. RNA immunoprecipitation (RIP)
RNA immunoprecipitation was performed using the EZ-Magna RIP
kit (Millipore) according to manufacturer's instructions. Brieﬂy,
1 × 107 cells were harvested and lysed with RIP lysis buffer with one
freeze–thaw cycle. Cell extracts were coimmunoprecipitated with
anti-EZh2 (Abcam) and SUZ12 (Abcam) and the retrieved RNA was
subjected to quantitative RT-PCR analysis. Anti-snRNP70 (Millipore)
was used as a positive control antibody, and normal mouse IgG was
used as a negative control. For quantitative RT-PCR analysis, U1
splicesome RNA was used as a non-speciﬁc control. Experiments were
done in biological triplicates.2.15. Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation was conducted with EZ-Magna
ChIP A/Gkit (Millipore) according tomanufacturer's instructions. Brieﬂy,
1 × 106 cells were used for each reaction. Cells were ﬁxed in 1% formal-
dehyde at room temperature for 10 min, the nucleus was isolated with
nuclear lysis buffer (Millipore) supplemented with protease inhibitor
cocktail (Millipore). Chromatin DNA was sonicated and sheared to a
length between 200 bp and 1000 bp. The sheared chromatin was
immunoprecipitated at 4 °C overnight with anti-H3K27me3 (Abcam).
Normal mouse IgG was used as a negative control and anti-RNA polII
(Millipore) was used as a positive control antibody. Protein A/G bead-
antibody/chromatin complexes were washed with low salt buffer, high
salt buffer, LiCl buffer and TE buffer to remove nonspeciﬁc binding.
Protein/DNA complex was reverse cross-linked and DNA was puriﬁed
using spin columns. Puriﬁed DNA was detected with quantitative PCR.
Primers for ChIP-qPCR were listed in Supplementary Table 1.2.16. Statistic analysis
All quantitative data are presented as the mean ± standard devi-
ation from at least three independent experiments. Unless otherwise
noted, the differences between two groups were analyzed using
Student's t test using SPSS 13.0. Metastasis-free survival and overall
survival were evaluated using the Kaplan–Meier method. The correla-
tion between linc-UBC1 and clinical and pathological characteristics
were analyzed using SPSS 13.0 Pearson Chi-square test. All tests
performed are two sided. Differences were considered statistically
signiﬁcant at p b 0.05.
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3.1. Microarray expression proﬁling identiﬁed many differentially
expressed lincRNAs in bladder cancer tissues compared with
normal adjacent tissues
To date, it is not yet clear whether large scale transcriptional
changes of lincRNAs occur in bladder cancer and if these changes
have functional roles in cancer onset and progression. As a ﬁrst
attempt to identify differentially expressed lincRNAs in bladder can-
cer tissues compared with normal adjacent tissues, we conducted
microarray analysis utilizing a microarray targeting 27958 Entrez
protein coding genes and 7419 lincRNAs (Agilent). Unsupervised hi-
erarchical clustering was used to analyze the differential lincRNA
expression proﬁles. Altogether, we identiﬁed 85 lincRNAs and 843
mRNAs that were differentially expressed in bladder cancer tissues
compared with normal adjacent tissues and were detected above
background (p b 0.05, fold change > 2) (Fig. 1A–B, Supplementary
Table 2).Fig. 1. lincRNAs are systemically dysregulated in bladder cancer tissues. A. Heat map rep
cancer (BCa) tissues compared with normal adjacent tissues (NAT). Each column repres
represents higher expression level and green color represents lower expression level. B.
level in bladder cancer (BCa) tissues compared with normal adjacent tissues (NAT). C. Hi
ysis. The red rectangular indicates the hybridization signal (replicate probes) of linc-UBC1
coding genes.3.2. Linc-UBC1 is frequently overexpressed in bladder cancer tissues
compared with normal adjacent tissues
Next, we sought to identify lincRNAs that were overexpressed in
bladder cancer. As an initial step, we focused on ﬁve lincRNAs
overexpressed in the microarray analysis with fold changes > 5. The
transcription locus of one of them overlaps with protein coding
gene and thus was excluded. We then quantiﬁed the four lincRNAs'
expression level in 10 independent cases of bladder cancer (Fig. S1)
and we named the one most frequently up-regulated in bladder can-
cer tissues linc-UBC1 (Up-regulated in bladder cancer 1) (Fig. 1C). In-
formation from GenBank shows that linc-UBC1 (GenBank accession
number BX640973) localizes in human chromosome 1q32.1 and has
a transcript of about 3 kb with just one exon (Fig. 1D). Next, we
further conﬁrmed its expression pattern in a larger sample size of
bladder cancer tissues.
We examined linc-UBC1 expression in 102 independent cases of
bladder cancer tissues and paired normal adjacent tissues using quanti-
tative RT-PCR, and fold change of >1.5 was designated as up-regulated.resenting unsupervised hierarchical clustering of mRNAs expression level in bladder
ents the indicated tissue sample, and each row indicates one mRNA. Red color scale
Heat map representing unsupervised hierarchical clustering of lincRNAs expression
gh resolution of the heat map showing linc-UBC1 expression in the microarray anal-
in BCa and NAT tissues. D. Genomic location of linc-UBC1 and its neighboring protein
Table 1
Characteristics of bladder cancer patients.
Characteristics Patients
frequency (%)
linc-UBC1 Chi-square p value
Low High
Total 102 42 (41.2%) 60 (58.8%)
Gender
Male 88 (86.3%) 37 51 0.2 0.655
1532 W. He et al. / Biochimica et Biophysica Acta 1832 (2013) 1528–1537We found that linc-UBC1wasup-regulated in 60 cases (58.8%) of bladder
cancer tissues compared with normal adjacent tissues, whereas 42 cases
(41.2%) are down-regulated or show no obvious changes (Fig. 2A,
Table 1). Statistical analysis revealed that linc-UBC1 overexpression cor-
relates with lymph node metastasis and shorter metastasis-free survival
and overall survival after surgery (Fig. 2B–C, Table 1). No statistical cor-
relation with gender, age, tumor stage and tumor grade was observed.Female 14 (13.7%) 5 9
Age (yr)
b65 61 (59.8%) 25 36 0.002 0.961
≥65 41 (40.2%) 17 24
Tumor stage
Ta, Tis, T1 39 (38.2%) 18 21 0.646 0.422
T2–4 63 (61.8%) 24 39
Lymph node status
N0 78 (76.5%) 37 41 5.36 0.021
N1, N2 24 (23.5%) 5 19
Tumor grade
G1 18 (17.6%) 7 11 0.047 0.828
G2–3 84 (82.4%) 35 493.3. linc-UBC1 is a bona ﬁde noncoding RNA and preferentially localizes
in the nucleus
First, to validate whether linc-UBC1 is a bona ﬁde non-coding RNA,
we employed TESTCODE tool to predict its protein-coding potential,
as it has a prediction accuracy of 95% [12]. A score of 0.472 was
achieved, whereas a score b0.74 means that the sequence is probably
noncoding, indicating that linc-UBC1 is probably a noncoding RNA.
Next, we examined the expression of linc-UBC1 in multiple blad-
der cancer cell lines. Fig. 2D shows the relative expression level of
linc-UBC1 in multiple bladder cancer cell lines, and the cell lines
that have relatively high levels of linc-UBC1 were chosen for further
knockdown assays.
We further investigated the subcellular localization of linc-UBC1,
as PRC2 complex exerts its epigenetic functions in the nucleus. As
expected, nuclear fractionation revealed that linc-UBC1 preferentially
localizes in the nucleus, whereas mRNAs mainly localize in the cyto-
plasm (Fig. 2E–F).Fig. 2. linc-UBC1 is frequently overexpressed in bladder cancer, acting as a negative pro
A. qRT-PCR analysis of linc-UBC1 expression level in 102 cases of bladder cancer tissues. Fo
dicated as linc-UBC1 low. B–C. Kaplan–Meier curves for metastasis-free survival (B) or ove
abundance of linc-UBC1 in multiple bladder cancer cell lines. Mean ± s.d. are shown. E–F
and J82. Small nuclear RNA U6 and GAPDH message RNA were used as positive control for3.4. linc-UBC1 regulates proliferation of bladder cancer cells
To further examine whether linc-UBC1 functions in bladder cancer
progression, in vitro functional studies were conducted. We knocked
down linc-UBC1 expression in J82, UMUC-3 and 5637 bladder cancer
cells using small interfering RNA (Fig. 3A). Linc-UBC1 depletiongnostic factor of metastasis and survival and preferentially localizes in the nucleus.
ld change of >1.5 is designated as overexpression (linc-UBC1 high), and the rest is in-
rall survival (C) of the 102 cases of bladder cancer patients measured in A. D. Relative
. linc-UBC1 preferentially localizes in the nucleus in bladder cancer cell line UMUC-3
nuclear and cytoplasm localization, respectively. Error bars = s.d., n = 3.
Fig. 3. linc-UBC1 knockdown attenuates bladder cancer cell proliferation. A. linc-UBC1 expression level was conﬁrmed by qRT-PCR in multiple bladder cancer cell lines. Mean ± s.d.
are shown. (n = 3). NC denotes siRNA having no homology to any known mammalian genes as a negative control. B–C. linc-UBC1 knockdown attenuated bladder cancer cell line
5637 and UMUC-3 proliferation as determined by MTT assay. Mean ± s.d. are shown. (n = 3). D. linc-UBC1 knockdown decreased bladder cancer cell line UMUC-3 in S phase. Blue
color represents the nucleus and red color indicates S phase cells (EdU positive). E. Histological analysis of the percent of EdU positive cells in negative control and linc-UBC1 knock-
down in bladder cancer cell line and primary culture of bladder cancer. Mean ± s.d. are shown. (n = 3). * indicates p b 0.05 between control cells and cells for linc-UBC1
knockdown.
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cell line UMUC-3 and 5637, as determined by MTT assay (Fig. 3B–C).
Further EdU incorporation analysis of S-phase cells showed that EdU
positive cells decreased signiﬁcantly after linc-UBC1 knockdown
(Fig. 3D–E). Importantly, the inhibitory effect of linc-UBC1 on cell pro-
liferation was also observed in primary cultured bladder cancer cells
from patients (Fig. 3E). Collectively, these results demonstrate a func-
tional requirement for linc-UBC1 expression for bladder cancer cell
proliferation.
3.5. linc-UBC1 regulates cell motility, invasion and colony formation
ability in vitro and tumorigenicity and metastatic potential in vivo
of bladder cancer cells
Cell motility, invasiveness and colony formation ability closely cor-
relate with cancer metastasis. We next examined whether linc-UBC1
knockdown affects these functions of bladder cancer cell. As shown in
Fig. 4A–F, linc-UBC1 knockdown signiﬁcantly decreased cell motility,
invasiveness and colony formation ability of bladder cancer cell lines
in vitro. Similarly, linc-UBC1 knockdown signiﬁcantly inhibited bladder
cancer cell tumorigenicity in vivo as compared with negative control
(Fig. 5A–C). To further validate the effect of linc-UBC1 knockdown on
metastatic potential of bladder cancer cell in vivo, we performed tail
vein xenografts and compared the lung wet weight. Linc-UBC1 knock-
down showed less lung colonization and lungwet weight than the neg-
ative control group (Fig. 5D–E). Collectively, these results showed thatlinc-UBC1 knockdown inhibits bladder cancer cell invasiveness and
metastasis in vitro and in vivo.3.6. linc-UBC1 acts in trans and binds to PRC2 complex in bladder
cancer cell
Next, we sought to determine whether linc-UBC1 acts in cis or in
trans to regulate target gene expression. We measured expression
level of linc-UBC1's neighboring genes by quantitative RT-PCR after
linc-UBC1 knockdown. As shown in Fig. 6A, no statistical changes
in the neighboring gene expression were observed, as represented
by KLHDC8A, LEMD and CDK18, indicating that linc-UBC1 may act
in trans.
It is estimated that up to 24% lincRNAs physically associate with
PRC2 [8]. Since so many lincRNAs bind to the PRC2 complex, we
asked whether linc-UBC1 also binds to the PRC2 complex. To test
this, we conducted a bioinformatic analysis to predict whether linc-
UBC1 can bind to EZH2 and SUZ12, core components of the PRC2 com-
plex. RNA–protein interaction prediction (RPISeq) obtained scores of
0.84 and 0.78 using SVM classiﬁer when predicting linc-UBC1-EZH2
and linc-UBC1-SUZ12 interaction, respectively. Predictions with prob-
abilities >0.5 were considered positive, and accuracies of the predic-
tion ranged from 57 to 99% in independent datasets of RNA–protein
interactions [13], suggesting that lincUBC1 probably interacts with
both EZH2 and SUZ12.
Fig. 4. linc-UBC1 knockdown inhibits bladder cancer cell migration, invasion and colony formation in vitro. A. Representative images of transwell assay after linc-UBC1 knockdown
in bladder cancer cell line J82 and UMUC-3. B. Histological analysis of OD (570 nm) absorbance of crystal violet-stained cells in transwell assay, mean ± s.d., n = 3. C. Represen-
tative images of Matrigel invasion assay after linc-UBC1 knockdown in bladder cancer cell line J82 and UMUC-3. D. Histological analysis of OD (570 nm) absorbance of crystal
violet-stained cells in Matrigel invasion assay, mean ± s.d., n = 3. E. Representative images of colony formation assay. F. Histological analysis of the number of colonies in control
and linc-UBC1 knockdown. Mean ± s.d. are shown. (n = 3).
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anti-EZH2 and anti-SUZ12 and the retrieved RNA was subjected to
quantitative reverse transcription PCR. An antibody to snRNP70,
a small nuclear ribonucleoprotein that associates with U1
spliceosomal RNA,was used as a positive control to conﬁrm the success
of the RIP assay. As shown in Fig. 6B–C, U1 was highly enriched in the
snRNP70 group, and an average of 14.8 and 11.2 fold enrichment was
achieved for linc-UBC1 in the EZH2 and SUZ12 groups respectively,
compared with the non-immuned IgG group. Similar results were ob-
served for lincRNA HOTAIR which is known to associate with the PRC2
complex [7]. No obvious enrichment was observed for non-speciﬁc con-
trol U1 splicesome RNA in EZH2 and SUZ12 group. These results suggest
that linc-UBC1 probably physically associates with the PRC2 complex.
We then askedwhether transcriptional changes of putative PRC2 tar-
gets occur after linc-UBC1, EZH2 and SUZ12 knockdown (Fig. 6D–E), re-
spectively. To answer this question, quantitative RT-PCR was conductedto examine the transcriptional changes of putative PRC2 targets pre-
viously conﬁrmed by ChIP-chip assay [14], and our results showed
that some putative PRC2 target genes, including CCND2, SERPINB2,
BMP2, KLF4 and HOXA5, showed derepression after linc-UBC1
knockdown (Fig. 6F). Furthermore, knockdown of EZH2 or SUZ12
resulted in similar derepression of these target genes (Fig. 6F) as
well.
We next performed chromatin immunoprecipitation (ChIP) to in-
vestigate whether linc-UBC1 or EZH2 knockdown results in alterations
in H3K27 methylation status of the common target genes of linc-UBC1
and PRC2. As determined by ChIP-qPCR, knockdown of linc-UBC1 or
EZH2 resulted in decreased trimethylation level of H3K27 in the pro-
moter regions of CCND2, SERPINB2, BMP2 and HOXA5 (Fig. 6G). Collec-
tively, these results demonstrate that linc-UBC1 exerts its function at
least in part by binding to PRC2 complex andmodulating histonemeth-
ylation by regulating PRC2 complex localization (Fig. 6H).
Fig. 5. linc-UBC1 knockdown inhibits bladder cancer cell tumorigenicity and metastatic potential in vivo. A–B. Representative images of tumorigenicity assay performed in NOD/SCID
mice. C. Histological analysis of tumor weight in control and linc-UBC1 knockdown group. Mean ± s.d. are shown. (n = 4). * indicates p b 0.05 between negative control and
linc-UBC1 knockdown group. D. Representative images of lungmetastasis of tail vein assay. Hematoxylin–eosin stain, 40× and 200×. E. Histological analysis of lungwet weight in control
and linc-UBC1 knockdown group. Mean ± s.d. are shown. (n = 4).
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Although thousands of lincRNAs were identiﬁed recently, functional
interpretation has just been started. Functional studies have indicated
that some lincRNAs are involved in human cancer pathogenesis, acting
as oncogenes or tumor suppressors [7,15]. In the current study, we
showed that linc-UBC1 is frequently overexpressed in bladder cancer
and its overexpression correlates with lymph node metastasis and
poor prognosis of bladder cancer patients, suggesting pro-oncogenic ac-
tivity of linc-UBC1. This observation is further supported by the follow-
ing functional studies showing that linc-UBC1 knockdown attenuates
bladder cancer cell proliferation, motility, invasion colony formation
ability in vitro, tumorigenicity and metastatic potential in vivo.
It is reported that some lincRNAs act in cis (on neighboring genes)
through transcriptional interference while the vast majority may
function in trans (on distant located genes) by targeting epigenetic
modiﬁers to distant particular genes [4,16,17], and even some
cis-regulating lncRNAs are found to have the capacity to act in trans
[17]. Here we identiﬁed that linc-UBC1 acts in trans and regulates tar-
get genes from different chromosomes, distant from the transcription
locus of itself, the same way as HOTAIR [7].Recent studies suggest that many lincRNAs participate in cancer
development by associating with histone modiﬁcation complexes,
such as PRC2. PRC2 complex functions as transcriptional repressor
and plays important roles in carcinogenesis and stem cell self-
renewal by represssing gene expression through modifying histone
3 lysine 27 methylation (H3K27) [18]. Overexpression of EZH2, a
key component of PRC2 complex, correlates with progression in
breast and prostate cancer progression [19,20]. The well character-
ized lincRNA HOTAIR interacts with PRC2 components SUZ12 and
EZH2 to promote cancer progression, including breast cancer [7],
gastrointestinal cancer [21] and hepatocellular carcinoma [22].
As molecular scaffold of histone modifying complexes, aberrant
lincRNA expression results in genome-wide re-targeting of the
PRC2 complex, leading to altered histone H3 lysine 27 methylation
and gene expression thus promoting cancer progression [7]. Here
we found that linc-UBC1 preferentially localizes in the nucleus
and provided evidence that linc-UBC1 physically associates with
the PRC2 complex and is frequently overexpressed in primary blad-
der cancer. After linc-UBC1 knockdown, derepression of putative
PRC2 target genes was observed, and similar ﬁndings were found
in EZH2 or SUZ12 knockdown assays, further supporting that at
Fig. 6. linc-UBC1 physically associates with PRC2 components EZH2 and SUZ12. A. The effect of linc-UBC1 knockdown on the expression of its neighboring genes. Error bars rep-
resent s.d. (n = 3). B. qRT-PCR analysis of small nuclear RNA U1 in RNA immunoprecipitation assay using anti-snRNP70 as a positive control antibody. Mean ± s.d. are shown.
(n = 3). * indicates p b 0.05. C. qRT-PCR analysis of linc-UBC1 and HOTAIR in RNA immunoprecipitation assay using anti-EZH2 and anti-SUZ12. RNA enrichment was determined
relative to the non-immuned IgG control. U1 was used as a non-speciﬁc control. Mean ± s.d. are shown. (n = 3). D. EZH2 and SUZ12 knockdown efﬁciency was conﬁrmed by
qRT-PCR. E. EZH2 and SUZ12 knockdown efﬁciency was conﬁrmed byWestern blot. F. qRT-PCR analysis of putative PRC2 target genes after linc-UBC1, EZH2 and SUZ12 knockdown,
respectively. Mean ± s.d. are shown. G. ChIP analysis of H3K27 trimethylation status of candidate linc-UBC1 target genes after knockdown assay. H. Working model of linc-UBC1
promoting bladder cancer metastasis. Linc-UBC1 induces PRC2 complex retargeting to regulate downstream target genes transcription.
1536 W. He et al. / Biochimica et Biophysica Acta 1832 (2013) 1528–1537least partially linc-UBC1 regulates downstream targets through
physically associating with the PRC2 complex. Chromatin immuno-
precipitation conﬁrmed that linc-UBC1 knockdown resulted indecreased H3K27 trimethylation, which explains the derepression
effect observed in potential target genes after linc-UBC1 or PRC2
silencing.
1537W. He et al. / Biochimica et Biophysica Acta 1832 (2013) 1528–1537We noticed that these target genes co-regulated by linc-UBC1
and PRC2 were not included in the differentially expressed mRNAs
in our microarray analysis of tissue samples. This could be explained
by: (1) Limited cases were included in the microarray analysis. No
statistical signiﬁcance could be found because of individual variance.
(2) Gene expression network in vivo is much more complex
than we expect. One gene is regulated by a series of the other genes,
which may have different regulatory patterns.
Lymph node metastasis is the strongest adverse pathological fea-
ture for overall survival of bladder cancer, and about 20–30% of pa-
tients with muscle invasive bladder cancer present with lymph
node metastasis [3]. Five year overall survival of bladder cancer pa-
tients with lymph node metastasis is approximately 30% [3]. Intense
efforts have been made to identify molecular predictive factors for
lymph node metastasis and survival of cancer patients. Tumor associ-
ated antigens, oncogenes, cell cycle regulators and other molecules
that potentially predict cancer recurrence and progression are widely
investigated [23]. Besides protein coding genes, noncoding RNAs are
also proved to posses potential diagnostic and prognostic values [8].
LincRNA HOTAIR has been associated with cancer progression and
considered as a negative prognostic factor for multiple cancer types
[7,21,22]. For lymph node metastasis, it is reported that increased
miR-127 expression and hypermethylation of miR-148a, miR-34b/c,
and miR-9 are associated with lymph node metastasis [24,25]. In
the current study, we observed that linc-UBC1 overexpression is asso-
ciated with lymph node metastasis and shorter metastasis-free sur-
vival and overall survival after surgery in bladder cancer patients,
providing the possibilities that linc-UBC1 may serve as molecular
prognostic factors to ﬁnd out the high-risk patients for further intense
treatment. This was further supported by the results that linc-UBC1
knockdown attenuated bladder cancer cell motility, invasiveness
and colony formation ability in vitro. More important, the inhibitory
effect of linc-UBC1 on cell proliferation was also observed in primary
bladder cancer cells obtained from patients. Further in vivo studies
showed that linc-UBC1 knockdown inhibits bladder cancer cell tu-
morigenicity and metastatic potential. Taken together, in vitro and
in vivo results are consistent with the observation that patients in
the linc-UBC1 overexpression group suffered relatively poor progno-
sis compared with those in the low expression group, and linc-UBC1
may serve as a candidate target for further bladder cancer target ther-
apy and molecular biomarkers of bladder cancer prognosis. Further
comparative studies assessing its sensitivity and speciﬁcity are ur-
gently needed. However, there are some limitations in this study.
Most of the cases in this study are muscle invasive bladder cancer,
and the follow up period is relatively short, so long-term follow up re-
sults are needed to further conﬁrm the prognostic value of linc-UBC1.
In summary, we have identiﬁed that a long intergenic noncoding
RNA, named linc-UBC1, is up-regulated in human primary bladder can-
cer tissues and serves as a negative prognostic factor for lymph node
metastasis and survival in bladder cancer patients. Knock down of
linc-UBC1 in bladder cancer cells inhibits cell proliferation, motility
and invasiveness in vitro and in vivo. Linc-UBC1 physically associates
with the PRC2 complex and could be an important regulator for bladder
cancer pathogenesis and candidate for further gene therapy.Accession numbers
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